Medicine News and Research

RSS

TPI announces formulation expansion program for GMOL

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the formulation expansion program for its flagship product Gingko Mihuan Oral Liquid.

4 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

Escitalopram reduces pain severity, interference in opioid-dependent patients

In what is believed to be the first study of its kind to demonstrate an association between the antidepressant escitalopram and improved general pain, researchers from Boston University School of Medicine (BUSM), have found that opioid-dependent patients treated with escitalopram experienced meaningful reductions in pain severity and pain interference during the first three months of therapy.

4 Nov 2011

Penn research group receives NCI grant to establish BETRNet

A research group at the Perelman School of Medicine of the University of Pennsylvania, led by John Lynch, MD, PhD, assistant professor of Medicine in the Division of Gastroenterology, has received a National Cancer Institute (NCI) grant to establish a Barrett's esophagus translational research network (BETRNet) with Columbia University and the Mayo Clinic.

4 Nov 2011

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Vertex Pharmaceuticals Incorporated today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO, a medicine in development that targets the defective protein that causes cystic fibrosis.

4 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

A prescription for prevention

Medicine-related hospital admissions could be reduced by a simple initiative designed and implemented by researchers at the University of Sydney’s Faculty of Pharmacy.

4 Nov 2011

Loneliness can affect sleep: Sleep

A new study from the American Academy of Sleep Medicine published in the Nov. 1 issue of the journal Sleep, suggests that loneliness could be significantly associated with sleep fragmentation, but not sleep duration or subjective sleep measures.

3 Nov 2011

POZEN third quarter revenue increases to $4.9 million

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2011.

3 Nov 2011

Gene therapy and stem cell transplantation successfully reverse hemophilia A

For the first time, researchers have combined gene therapy and stem cell transplantation to successfully reverse the severe, crippling bleeding disorder hemophilia A in large animals, opening the door to the development of new therapies for human patients.

3 Nov 2011

First Edition: November 3, 2011

Today's headlines include reports about a bipartisan group of lawmakers who are urging the super committee to consider "all options."

3 Nov 2011

Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide

Clinuvel Pharmaceuticals Limited, a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE.

3 Nov 2011

Breakdown of unsaturated fats can induce complications in obese patients with acute pancreatitis

The toxic byproducts produced by the breakdown of unsaturated fats lead to a higher likelihood of severe inflammation, cell death and multi-system organ failure among acute pancreatitis patients who are obese, say researchers at the University of Pittsburgh School of Medicine.

3 Nov 2011

JDC receives NIDDK grant for research into diabetic retinopathy, kidney disease

Joslin Diabetes Center has received a $3.9 million DP3 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to identify protective factors that enable many Joslin 50-Year Medalists to remain free of commonly occurring diabetes complications.

3 Nov 2011

Elsevier's 2012 eBook Frontlist collections available on SciVerse ScienceDirect

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announced today that its 2012 eBook Frontlist collections are available for advance purchase on SciVerse ScienceDirect, Elsevier's online platform for scientific content.

3 Nov 2011

Role of cardiovascular magnetic resonance in clinical cardiology

Cardiovascular Magnetic Resonance (CMR) has undergone substantial development and offers important advantages compared with other well-established imaging modalities.

3 Nov 2011

BUSM researcher receives two NIH grants to study scleroderma

Boston University School of Medicine (BUSM) researcher Robert Lafyatis, MD, recently was awarded two grants from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases.

3 Nov 2011

Thromboelastograph analyzer can help save lives of trauma patients

Researchers from the University of Notre Dame's Keck Center and trauma physicians at South Bend's Memorial Hospital are joining forces to use a new medical technology to help save the lives of trauma patients.

3 Nov 2011

Benefits of combined therapy for men with high-risk prostate cancer

Men with locally advanced or high-risk prostate cancer who receive combined radiation and hormone therapy live longer and are less likely to die from their disease, shows clinical research led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network.

3 Nov 2011

Exenatide's rapid anti-inflammatory effect may inhibit atherosclerosis

Exenatide, a drug commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at Buffalo study has shown.

3 Nov 2011